Back to Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 1

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features

Authors Antonini A, Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Onofrj M, Zappia M, Quattrone A

Published 8 February 2008 Volume 2008:4(1) Pages 1—9

DOI https://doi.org/10.2147/NDT.S2404


Angelo Antonini1, Giovanni Abbruzzese2, Paolo Barone3, Ubaldo Bonuccelli4, Leonardo Lopiano5, Marco Onofrj6, Mario Zappia7, Aldo Quattrone8

1Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy; 2Movement Disorder Unit, Neurology, University of Genoa, Genoa, Italy; 3Dipartimento di Scienze Neurologiche, Università di Napoli Federico II, Naples, Italy; 4University of Pisa, Department of Neuroscience, Pisa, Italy; 5Department of Neuroscience, University of Turin, Turin, Italy; 6Department of Oncology and Neuroscience, University G D’Annunzio, G D’Annunzio Foundation CESI, Chieti-Pescara, Italy; 7Department of Neurosciences, University of Catania; 8Institute of Neurology, University “Magna Græcia,” Catanzaro, Italy

Abstract: Levodopa is the most effective treatment in Parkinson’s disease and the association with COMT inhibitors widens its plasma bioavailability and effectiveness. Tolcapone is a potent COMT inhibitor whose utilization in PD is limited due to safety concerns on liver toxicity. However, recent data indicate that if liver function is actively monitored, tolerability is no worse than other currently available therapies. By contrast, administration of tolcapone is associated with significant clinical improvement and benefit involves also non-motor features. In this review we discuss the rationale for the use of tolcapone in association with levodopa and other treatments in PD, and we provide an indirect comparison of current strategies to reduce “off” time. We propose that future guidelines include a trial with tolcapone in all PD patients who continue to complain about motor fluctuations despite treatment with entacapone and/or MAO-B inhibitors. Moreover, we suggest that tolcapone should be considered before surgical or infusional strategies are applied.

Keywords: Parkinson’s disease, levodopa, motor fluctuations, COMT inhibitors, tolcapone

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]